| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals
|
Aug 11, 2026 | BUY |
Strong Buy
+252.5% avg upside
16 analysts
|
$24.00
130.14% Upside
|
+0.0% | · |
|
DMRA
Damora Therapeutics
|
Aug 11, 2026 | BUY |
Strong Buy
-4.7% avg upside
20 analysts
|
$45.00
48.12% Upside
|
· | · |
|
SYRE
Spyre Therapeutics
|
Aug 11, 2026 | BUY |
Strong Buy
-8.7% avg upside
23 analysts
|
$129.00
25.50% Upside
|
· | · |
|
ORKA
Oruka Therapeutics
|
Aug 11, 2026 | BUY |
Strong Buy
+20.5% avg upside
16 analysts
|
$175.00
67.13% Upside
|
+0.0% | · |
|
COGT
Cogent Biosciences
|
Aug 10, 2026 | BUY |
Strong Buy
-4.4% avg upside
26 analysts
|
$55.00
42.09% Upside
|
-6.7% | · |
|
ELVN
Enliven Therapeutics
|
Aug 08, 2026 | BUY |
Strong Buy
-1.9% avg upside
14 analysts
|
$70.00
19.15% Upside
|
+0.0% | · |
|
IMVT
Immunovant
|
Aug 07, 2026 | BUY |
Strong Buy
-1.8% avg upside
24 analysts
|
$53.00
29.43% Upside
|
+6.6% | · |
|
CGON
CG Oncology, Inc.
|
Aug 07, 2026 | BUY |
Strong Buy
+11.8% avg upside
17 analysts
|
$108.00
40.29% Upside
|
+2.6% | · |
|
CLDX
Celldex
|
Aug 07, 2026 | BUY |
Strong Buy
-6.9% avg upside
28 analysts
|
$56.00
26.23% Upside
|
-0.0% | · |
|
IFRX
InflaRx
|
Aug 06, 2026 | BUY |
Buy
+348.8% avg upside
11 analysts
|
$5.00
150.02% Upside
|
+7.0% | · |
|
ALXO
ALX Oncology Holdings
|
Aug 06, 2026 | HOLD |
Strong Buy
+829.7% avg upside
11 analysts
|
— | -6.2% | · |
|
OKUR
OnKure Therapeutics
|
Aug 05, 2026 | BUY |
Buy
+480.9% avg upside
13 analysts
|
$16.00
291.11% Upside
|
-0.5% | · |
|
PVLA
Palvella Therapeutics
|
Aug 05, 2026 | BUY |
Strong Buy
+9.4% avg upside
27 analysts
|
$236.00
52.98% Upside
|
-0.4% | · |
|
TSE:EPRX
Eupraxia Pharmaceuticals
|
Jul 31, 2026 | BUY |
Strong Buy
+138.7% avg upside
9 analysts
|
$22.32
138.82% Upside
|
+5.3% | · |
|
QNCX
Quince Therapeutics
|
Jul 30, 2026 | BUY |
Buy
+564.2% avg upside
16 analysts
|
$99.00
202.51% Upside
|
+31.1% | · |
|
TCRX
TScan Therapeutics
|
Jul 29, 2026 | BUY |
Strong Buy
+995.3% avg upside
12 analysts
|
$6.00
672.42% Upside
|
+2.7% | · |
|
DBVT
DBV Technologies SA - American
|
Jul 17, 2026 | BUY |
Buy
+70.4% avg upside
15 analysts
|
$45.00
219.43% Upside
|
-2.9% | · |
|
AVBP
ArriVent BioPharma, Inc.
|
Jul 14, 2026 | BUY |
Strong Buy
+35.6% avg upside
15 analysts
|
$42.00
33.86% Upside
|
-6.2% | · |
|
ABVX
Abivax SA Sponsored ADR
|
Jun 30, 2026 | BUY |
Strong Buy
+6.0% avg upside
15 analysts
|
$170.00
34.02% Upside
|
-5.8% | · |
|
PYXS
Pyxis Oncology
|
May 23, 2026 | BUY |
Strong Buy
+159.7% avg upside
14 analysts
|
$6.00
112.03% Upside
|
+128.8% | · |
|
IMUX
Immunic
|
May 16, 2026 | BUY |
Strong Buy
+158.7% avg upside
21 analysts
|
$56.00
261.67% Upside
|
+22.6% | · |
|
GYRE
Gyre Therapeutics
|
Aug 09, 2023 | HOLD |
Strong Buy
+210.5% avg upside
15 analysts
|
— | +103.9% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.